Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Chang Liu, Navindra P. Seeram, Hang Ma
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer (2022) Vol. 22, Iss. 3, pp. 174-189
Open Access | Times Cited: 266
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 173
Small molecule-based immunomodulators for cancer therapy
Yinrong Wu, Zichao Yang, Kui Cheng, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4287-4308
Open Access | Times Cited: 67
Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma
Jingwen Zhang, Anthony M. Joshua, Yue Li, et al.
Cancer Letters (2024) Vol. 586, pp. 216633-216633
Open Access | Times Cited: 8
Tumor lysates-constructed hydrogel to potentiate tumor immunotherapy
Xiangwu Chen, Zeyu Jiang, Yang Lin, et al.
Journal of Controlled Release (2023) Vol. 358, pp. 345-357
Closed Access | Times Cited: 20
Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening
Katarzyna Ratajczak, Hubert Grel, Piotr Olejnik, et al.
Biosensors and Bioelectronics (2023) Vol. 240, pp. 115644-115644
Open Access | Times Cited: 18
Designing temporal- and spatial-control multifunctional nanoformulations for synergistic photodynamic–enhanced tumour immunotherapy
Ping Zhang, Yanyan Cui, Yaling Wang
Nano Today (2023) Vol. 49, pp. 101816-101816
Closed Access | Times Cited: 17
Assembling Au8 clusters on surfaces of bifunctional nanoimmunomodulators for synergistically enhanced low dose radiotherapy of metastatic tumor
Rui Zhang, Mengchao Jia, Hongying Lv, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors
Tongfei Jing, Zhijing Zhang, Zhenghui Kang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 10, pp. 6811-6835
Closed Access | Times Cited: 14
Nanotechnology Applications in Breast Cancer Immunotherapy
Ruijie Wang, Pramod Kumar, Moataz Reda, et al.
Small (2023)
Closed Access | Times Cited: 13
The Groebke–Blackburn–Bienaymé reaction in its maturity: innovation and improvements since its 21st birthday (2019–2023)
Cristina Martini, Muhammad Idham Darussalam Mardjan, Andrea Basso
Beilstein Journal of Organic Chemistry (2024) Vol. 20, pp. 1839-1879
Open Access | Times Cited: 5
Atypical artificial cells: Novel biomimetic materials for combating cancer
Zhao‐yang Ren, Qianqian Wan, Yi‐na Zhu, et al.
Interdisciplinary materials (2024) Vol. 3, Iss. 5, pp. 658-714
Open Access | Times Cited: 4
Exploring the interaction mechanism between the programmed death-ligand 1 protein and scutellarin via multi-spectroscopy and computer simulation
Yijun Tu, Yijie Cai, Jiachuan Lei, et al.
International Journal of Biological Macromolecules (2025) Vol. 294, pp. 139492-139492
Closed Access
Unveiling 2-Isopropyl-5-methylphenol’s Immunomodulatory Potential in Breast Cancer: A Synergistic Computational and Laboratory Investigation
Muhammad Irfan Bashir, Muhammad Usman Rashid, Naila Malkani
The Journal of Steroid Biochemistry and Molecular Biology (2025) Vol. 248, pp. 106702-106702
Closed Access
A Comparative Molecular Dynamics Study of Food-Derived Compounds as PD-L1 Inhibitors: Insights Across Six Flavonoid Subgroups
Dejun Jiang, Hyuk-Ku Kwon, Oh Wook Kwon, et al.
Molecules (2025) Vol. 30, Iss. 4, pp. 907-907
Open Access
Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner
Mark B. Wiley, Jessica Bauer, Valentina Álvarez, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Investigation the immunotherapeutic potential of miR-4477a targeting PD-1/PD-L1 in breast cancer cell line using a CD8+ co-culture model
Yasin Tülüce, Sedat Köstekci, Fuat Karakuş, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Luminescent Binuclear Pd (II) N^C^N‐Pincer Complexes With N^N Bridging Ligand
Xiaping Zhu, Yunjun Shen, Yuzhen Zhang
Applied Organometallic Chemistry (2025) Vol. 39, Iss. 5
Closed Access
Targeted protein degradation with small molecules for cancer immunotherapy
Zichao Yang, Jianwei Xu, Xixiang Yang, et al.
Asian Journal of Pharmaceutical Sciences (2025), pp. 101058-101058
Open Access
Sokotrasterol Sulfate Suppresses IFN-γ-Induced PD-L1 Expression by Inhibiting JAK Activity
Xiaobo Wang, Wenlong Xu, Zeng-Yiyi Wang, et al.
Journal of Natural Products (2024) Vol. 87, Iss. 4, pp. 713-721
Closed Access | Times Cited: 3
A novel biomimetic nanoplasmonic sensor for rapid and accurate evaluation of checkpoint inhibitor immunotherapy
Razia Batool, Maria Soler, Rukmani Singh, et al.
Analytical and Bioanalytical Chemistry (2024)
Open Access | Times Cited: 3
Role of PD‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
Neha Sharma, Rupa Mazumder, Pallavi Rai, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 3
Closed Access | Times Cited: 3
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Clemens Zwergel, Rossella Fioravanti, Antonello Mai
Drug Discovery Today (2022) Vol. 28, Iss. 2, pp. 103435-103435
Closed Access | Times Cited: 15
In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Chih‐Hao Lu, Wei-Min Chung, Chun‐Hao Tsai, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 13
Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects
Abid H. Banday, Mohnad Abdalla
Current Medicinal Chemistry (2022) Vol. 30, Iss. 28, pp. 3215-3237
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top